Evropska unija - slovenščina - EMA (European Medicines Agency)

eurocept international b. v. - natrijev phenylbutyrate - carbamoyl-fosfat sintetaze sem pomanjkljivost bolezni - različne zdravljene bolezni prebavil in presnove izdelki - zdravljenje kroničnih upravljanje sečnine-cikel motnje.

Evropska unija - slovenščina - EMA (European Medicines Agency)

pfizer limited - celecoxib - adenomatozna polipoza coli - antineoplastična sredstva - onsenal je indiciran za zmanjšanje števila adenomatoznih črevesnih polipov v družinski adenomatozni polipoziji (fap), kot dopolnilo kirurgiji in nadaljnjemu endoskopskemu nadzoru (glejte poglavje 4. učinek onsenal povzroča zmanjšanje polyp breme tveganja črevesni rak še ni bila dokazana (glej točki 4. 4 in 5.

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

veyx -

Evropska unija - slovenščina - EMA (European Medicines Agency)

pierre fabre medicament - neratinib - neoplazme dojke - antineoplastična sredstva - nerlynx je označen za podaljšano adjuvant zdravljenje odraslih bolnikov z zgodnji fazi hormon receptor her2 pozitiven-overexpressed/dopolniti rak dojke, ki so manj kot eno leto od zaključka pred adjuvant trastuzumab, ki temelji terapija.

Evropska unija - slovenščina - EMA (European Medicines Agency)

grunenthal gmbh - allopurinol, lesinurad - protin - antigout pripravki - duzallo je navedeno pri odraslih za zdravljenje hyperuricaemia v protin bolnikih, ki niso dosegli cilja serum ravni sečne kisline z ustrezno dozo allopurinol sam.

Evropska unija - slovenščina - EMA (European Medicines Agency)

merck sharp & dohme b.v. - doravirine, lamivudine, tenofovir disoproxil fumarate - okužbe z virusom hiv - antivirusi za zdravljenje okužb z virusom hiv, kombinacije - delstrigo je indiciran za zdravljenje odraslih, okuženih z virusom hiv 1 brez preteklosti ali sedanjosti dokazov odpornost proti nnrti razred, lamivudine, ali tenofovir. delstrigo is also indicated for the treatment of adolescents aged 12 years and older weighing at least 35 kg who are infected with hiv-1 without past or present evidence of resistance to the nnrti class, lamivudine, or tenofovir and who have experienced toxicities which preclude the use of other regimens that do not contain tenofovir disoproxil.

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

intervet international -

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

boehringer ingelheim animal health france scs 29 avenue tony garnier -

Evropska unija - slovenščina - EMA (European Medicines Agency)

janssen-cilag international n.v. - abiraterone acetate, niraparib tosilate monohydrate - prostatic neoplazem, kastracija-odporne - antineoplastična sredstva - treatment of adult patients with prostate cancer.

Evropska unija - slovenščina - EMA (European Medicines Agency)

accord healthcare s.l.u. - imatinib - precursor cell lymphoblastic leukemia-lymphoma; dermatofibrosarcoma; myelodysplastic-myeloproliferative diseases; leukemia, myelogenous, chronic, bcr-abl positive; hypereosinophilic syndrome - imatinib - imatinib accord is indicated for the treatment of- adult and paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment. - adult and paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis. - adult and paediatric patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy. - adult patients with relapsed or refractory ph+ all as monotherapy. - adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements. - adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfrα rearrangement. - adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) and adult patients with recurrent and/or metastatic dfsp who are not eligible for surgery. - the treatment of adult patients with kit (cd 117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (gist). - the adjuvant treatment of adult patients who are at significant risk of relapse following resection of kit (cd117)-positive gist. patients who have a low or very low risk of recurrence should not receive adjuvant treatmentthe effect of imatinib on the outcome of bone marrow transplantation has not been determined. in adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in cml, on haematological and cytogenetic response rates in ph+ all, mds/mpd, on haematological response rates in hes/cel and on objective response rates in adult patients with unresectable and/or metastatic dfsp. the experience with imatinib in patients with mds/mpd associated with pdgfr gene re-arrangements is very limited (see section 5. razen v novo diagnozo kronične faze cml, ni kontroliranih preskušanjih, dokazujejo kliničnih koristi ali poveča preživetje pri teh bolezni. .